Wisconsin has seen a doubling of women on Medicaid with hepatitis C infection in pregnancy which resulted in an increase of babies being afflicted with the liver disease. This rapid rise of cases is attributed to the needle-sharing practices of a rising number of people addicted to opiates.
CDC estimates a 6 percent mother-to-child transmission rate nationwide which underscores the need for testing of pregnant women for the disease and an intensive education campaign to increase awareness of the disease among this population.
For more information, see https://www.drugs.com/news/tiny-opioid-victims-addicted-moms-transmit-hepatitis-c-67525.html
5 inmates afflicted with Hepatitis in Minnesota sue the state for highly effective direct acting retrovirals. These drugs have cure rates of 95% but are priced from $26,400 to over $ 100,000 per patient.
The FDA has recently approved Mavyret, a combination of glecaprevir and pribentasvir, for Hepatitis C Genotype 1-6 without cirrhosis. The new drug shortens a previous 12-week treatment to 8 weeks. It is also an additional option for patients who have not been successful previously.
For more information, see https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm
A report published by the CDC Morbidity and Mortality Weekly Report correlated the lack of policy on injection drug users with an increase incidence of infection of Hepatits C. Most of these States new cases of the disease were attributed to this population but the States lack a tailored policy for this segment of the population.